119479-32-2

Usage

Uses

Used in Organic Synthesis:
2-(Tert-Butoxycarbonylamino)Pent-4-Enoic Acid is used as a building block for the preparation of various compounds, contributing to the structural diversity and functional groups in synthesized molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(Tert-Butoxycarbonylamino)Pent-4-Enoic Acid is utilized as a key intermediate in the development of new drug candidates. Its unique structure allows for the exploration of its therapeutic properties and potential applications in medicine.
Used as a Protecting Group in Peptide Synthesis:
As a tert-butoxycarbonylamino derivative, 2-(Tert-Butoxycarbonylamino)Pent-4-Enoic Acid serves as a protecting group for the amino function in peptide synthesis. This role is crucial for enabling selective modification of the molecule, which is essential in the synthesis of complex peptide sequences and the development of peptide-based drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(Tert-Butoxycarbonylamino)Pent-4-Enoic Acid is employed to develop new drug candidates with potential therapeutic properties. Its versatile chemical structure allows for the design and synthesis of compounds that can target specific biological pathways or receptors, offering novel treatment options for various diseases and conditions.

Upstream product

• 4530-20-5 BOC-glycine 
• 106-95-6 allyl bromide 
• 1069-48-3 rac-allylglycine 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 68843-72-1 ethyl 2-aminopent-4-enoate 
• 106928-50-1 methyl 2-[(tert-butoxycarbonyl)amino]pent-4-enoate 
• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 124373-83-7 allyl 2-(tert-butoxycarbonylamino)acetate 
• 3182-77-2 N-allylglycine 
• 115289-57-1 ethyl N-(diphenylmethylene)-2-amino-4-pentenoate 
• 135722-56-4 ethyl (RS)-N-(tert-butoxycarbonyl)-2-aminopent-4-enoate 
• 1538-75-6 2,2-dimethylpropanoic anhydride 

Downstream Products

• 106928-50-1 methyl 2-[(tert-butoxycarbonyl)amino]pent-4-enoate 
• 183867-12-1 (1-{Benzyl-[(Z)-4-(3-ethoxy-phenoxy)-but-2-enyl]-carbamoyl}-but-3-enyl)-carbamic acid tert-butyl ester 
• 274918-46-6 tert-butyl (1-oxopent-4-en-2-yl)carbamate 
• 918306-87-3 (+/-)-tert-butyl (1-((allyl(benzyl)amino)carbonyl)but-3-en-1-yl)carbamate 
• 959408-01-6 Boc-allylglycine-N-(2,4-dimethoxybenzyl)allylglycine methyl ester 
• 851626-48-7 (2RS,1'S,2'E) 2-(tert-butoxycarbonylamino)pent-4-enoic acid 4'-(tert-butyl(diphenyl)silyloxy)-1'-methylbut-2'-enyl ester 
• 761402-01-1 (1-{allyl-[3-(methyl-diphenyl-silanyl)-allyl]-carbamoyl}-but-3-enyl)-carbamic acid tert-butyl ester 
• 183867-13-2 (+/-)-tert-butyl (1-benzyl-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)carbamate 
• 135263-84-2 (1R,2S,5R)-5-methyl-2-(1-methyl-1-phenylethyl)cyclohexyl (2S)-2-<(tert-butoxycarbonyl)amino>pent-4-enoate 
• 145280-05-3 (1R,2S,5R)-5-methyl-2-(1-methyl-1-phenylethyl)cyclohexyl (2R)-2-<(tert-butoxycarbonyl)amino>pent-4-enoate 

Relevant academic research and scientific papers

Modified N-acyl-homoserine lactones as chemical probes for the elucidation of plant-microbe interactions

Gram-negative bacteria often use N-acyl-homoserine lactones (AHLs) as signal molecules to monitor their local population densities and to regulate gene-expression in a process called "Quorum Sensing" (QS). This cell-to-cell communication allows bacteria to adapt to environmental changes and to behave as multicellular communities. QS plays a key role in both bacterial virulence towards the host and symbiotic interactions with other organisms. Plants also perceive AHLs and respond to them with changes in gene expression or modifications in development. Herein, we report the synthesis of new AHL-derivatives for the investigation and identification of AHL-interacting proteins. We show that our new compounds are still recognised by different bacteria and that a novel biotin-tagged-AHL derivative interacts with a bacterial AHL receptor.

Direct synthesis of Boc protected (D,L)-amino acids from Boc-glycine

Boc-glycine is easily deprotonated by lithium diisopropylamide, yielding a trianion which is trapped with an electrophile to give access to Boc-(D,L)-amino acids.

Amino [13]-macrodilactones: Synthesis, derivatization, and structural motifs

Macrocycles draw their usefulness from an ability to balance size, shape, and functionality according to general principles. These structural parameters manifest as the conformations of macrocycles and ultimately their functions. Reported here are results of an investigation on [13]-macrodilactones that take up unique folded conformations based on the interplay of multi-atom planar units and sterics. The defining feature of this group of [13]-macrodilactones is the pendant amine group attached to the ring. Amidation of the ring generated analogs that were designed to imitate features of the macrocyclic natural product Teixobactin. We also show that intramolecular interactions, and the A-value of an acylated amine can explain the conformational preferences in macrocycles.

New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity

A series of twelve fluorinated and non-fluorinated potential histone deacetylase inhibitors 25 was synthesized and their inhibitory activity was tested against rat liver histone deacetylase. The new inhibitors involve an enzyme binding element consisting of asparagine, glutamine or different short chain fluorinated or unfluorinated amino acids, a suberoyl spacer and a hydroxamic acid functionality, which is responsible for the inhibitory activity. The 4-fluoro-2-aminobutyric acid esters 1a,b, their 2-methyl derivatives 2a,b and the 2-amino-4-fluoropent-4-enoic acid esters 3a,b were synthesized by alkylation of glycine or alanine ester imides with bromofluoroethane or 2-fluoroallylbromide, respectively. Methyl 2-amino-5-fluorohex-5-enoate (4a) was prepared using 3-fluorobut-3-enyl tosylate or the iodide as alkylating reagents. An alternative pathway starting from Boc protected 3-iodo-L-alanine was more efficient. The latter method was also applied to synthesize the parent unfluorinated compound 4c using allylbromide as the alkylating reagent. The fluorinated compounds, tested as histone deacetylase inhibitors were slightly less active than comparable (S)-valine, (S)-phenylalanine or (S)-allylglycine derivatives that do not contain a fluorine atom. Interestingly, it was shown for the first time that the fluoro vinyl group which was proposed to be an aprotic amide mimic due to its electronic properties may serve as a bioisosteric replacement of a primary amide function. For the fluorinated analogs 25f (IC50 0.88 μM) and 25i (IC50 1.02 μM) a similar or an even enhanced inhibitory activity was observed compared to the unfluorinated parents 25g (IC50 0.67 μM) and 25j (IC50 1.79 μM) or the (S)-asparagine or (S)-glutamine derivatives 25l (IC50 2.10 μM) and 25m (IC50 3.90 μM).

THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA

A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS

A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.

THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS

A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.

3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF ARWAY DISEASES

A compound of Formula (I) in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

NOVEL LACTAME DERIVATIVES AS RENIN INHIBITORS

The invention relates to novel lactame derivatives, related compounds and use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compo

GLYCINE DERIVATIVE AND USE THEREOF

A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.